|
gptkbp:instanceOf
|
gptkb:drug
gptkb:insulin
|
|
gptkbp:approvalYear
|
2000
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10AB05
|
|
gptkbp:brand
|
gptkb:Fiasp
gptkb:NovoLog
|
|
gptkbp:CASNumber
|
133972-88-2
|
|
gptkbp:color
|
clear
|
|
gptkbp:developedBy
|
gptkb:Novo_Nordisk
|
|
gptkbp:differenceFromHumanInsulin
|
proline at position B28 replaced by aspartic acid
|
|
gptkbp:duration
|
3-5 hours
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
81 minutes
|
|
gptkbp:hasMolecularFormula
|
C256H381N65O79S6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Insulin aspart
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
lowers blood glucose by stimulating glucose uptake
|
|
gptkbp:onset
|
10-20 minutes
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:product
|
recombinant DNA
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
allergic reactions
lipodystrophy
|
|
gptkbp:storage
|
2-8°C (refrigerated)
|
|
gptkbp:usedFor
|
gptkb:diabetes_mellitus_type_2
diabetes mellitus type 1
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:insulin
|
|
gptkbp:bfsLayer
|
6
|